The US Food and Drug Administration says hydroxychloroquine and chloroquine do not appear to be effective in treating COVID-19 patients.
On June 15, the US Food and Drug Administration (FDA) revoked the licensing of emergency use of two antimalarial drugs hydroxychloroquine and chloroquine to treat COVID-19 patients.
According to CBS News, the FDA said that based on their ongoing review of available scientific evidence, they determined the drug was “unlikely to be effective in treating COVID-19”.
Citing a number of reports of heart-related side effects, the FDA says the benefits of these drugs have yet to be substantiated, while the currently known benefits “are no longer significant. known risks and potential risks “.
Hydroxychloroquine (HCQ) and chloroquine (CQ) were approved for use in March after they were thought to be able to cope with COVID-19 and early studies appear to show that they are effective in humans. That was also the time when the number of infections surged in the United States.
In March, US President Donald Trump also praised the use of hydroxychloroquine as having “a real opportunity to become one of the biggest game-changing things in medical history.”
However, some later studies have suggested that they are not as effective in treating and preventing COVID-19. British scientists earlier this month stopped a major test after evaluating “unhelpful” hydroxychloroquine in treating COVID-19 patients.
The FDA’s decision also means that the federal government will stop shipping the two drugs to state and local health officials to treat COVID-19 patients. The White House has not yet responded to a request for comment on the FDA’s move, according to CBS News.